Literature DB >> 34265061

EEG findings in CAR T-cell-associated neurotoxicity: Clinical and radiological correlations.

Isabelle Beuchat1, Husain H Danish1,2, Daniel B Rubin1,2, Caron Jacobson3, Matthew Robertson4, Henrikas Vaitkevicius1, Jong Woo Lee1.   

Abstract

BACKGROUND: While EEG is frequently reported as abnormal after chimeric antigen receptor (CAR) T-cell therapy, its clinical significance remains unclear. We aim to systematically describe EEG features in a large single-center cohort and correlate them with clinical and radiological findings.
METHODS: We retrospectively identified patients undergoing CAR T-cell therapy who had continuous EEG. Neurotoxicity grades, detailed neurological symptoms, and brain MRI or FDG-PET were obtained. Correlation between clinical and radiological findings and EEG features was assessed.
RESULTS: In 81 patients with median neurotoxicity grade 3 (IQR 2-3), diffuse EEG background slowing was the most common finding and correlated with neurotoxicity severity (P <.001). A total of 42 patients had rhythmic or periodic patterns, 16 of them within the ictal-interictal-continuum (IIC), 5 with clinical seizures, and 3 with only electrographic seizures. Focal EEG abnormalities, consisting of lateralized periodic discharges (LPD, n = 1), lateralized rhythmic delta activity (LRDA, n = 6), or focal slowing (n = 19), were found in 22 patients. All patients with LRDA, LPD, and 10/19 patients with focal slowing had focal clinical symptoms concordant with these EEG abnormalities. In addition, these focal EEG changes are often correlated with PET hypometabolism or MRI hypoperfusion, in absence of a structural lesion.
CONCLUSION: In adult patients experiencing neurotoxicity after CAR T-cell infusion, EEG degree of background disorganization correlated with neurotoxicity severity. IIC patterns and focal EEG abnormalities are frequent and often correlate with focal clinical symptoms and with PET-hypometabolism/MRI-hypoperfusion, without structural lesion. The etiology of these findings remains to be elucidated.
© The Author(s) 2021. Published by Oxford University Press on behalf of the Society for Neuro-Oncology. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.

Entities:  

Keywords:  CAR T cell; EEG; ICANS; PET; neurotoxicity

Mesh:

Year:  2022        PMID: 34265061      PMCID: PMC8804895          DOI: 10.1093/neuonc/noab174

Source DB:  PubMed          Journal:  Neuro Oncol        ISSN: 1522-8517            Impact factor:   13.029


  46 in total

1.  Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1-2 trial.

Authors:  Frederick L Locke; Armin Ghobadi; Caron A Jacobson; David B Miklos; Lazaros J Lekakis; Olalekan O Oluwole; Yi Lin; Ira Braunschweig; Brian T Hill; John M Timmerman; Abhinav Deol; Patrick M Reagan; Patrick Stiff; Ian W Flinn; Umar Farooq; Andre Goy; Peter A McSweeney; Javier Munoz; Tanya Siddiqi; Julio C Chavez; Alex F Herrera; Nancy L Bartlett; Jeffrey S Wiezorek; Lynn Navale; Allen Xue; Yizhou Jiang; Adrian Bot; John M Rossi; Jenny J Kim; William Y Go; Sattva S Neelapu
Journal:  Lancet Oncol       Date:  2018-12-02       Impact factor: 41.316

Review 2.  Tisagenlecleucel in pediatric patients with acute lymphoblastic leukemia.

Authors:  Shannon L Maude
Journal:  Clin Adv Hematol Oncol       Date:  2018-10

3.  Neurological toxicities associated with chimeric antigen receptor T-cell therapy.

Authors:  Daniel B Rubin; Husain H Danish; Ali Basil Ali; Karen Li; Sarah LaRose; Andrew D Monk; David J Cote; Lauren Spendley; Angela H Kim; Matthew S Robertson; Matthew Torre; Timothy R Smith; Saef Izzy; Caron A Jacobson; Jong Woo Lee; Henrikas Vaitkevicius
Journal:  Brain       Date:  2019-05-01       Impact factor: 13.501

Review 4.  Chimeric antigen receptor T-cell therapy - assessment and management of toxicities.

Authors:  Sattva S Neelapu; Sudhakar Tummala; Partow Kebriaei; William Wierda; Cristina Gutierrez; Frederick L Locke; Krishna V Komanduri; Yi Lin; Nitin Jain; Naval Daver; Jason Westin; Alison M Gulbis; Monica E Loghin; John F de Groot; Sherry Adkins; Suzanne E Davis; Katayoun Rezvani; Patrick Hwu; Elizabeth J Shpall
Journal:  Nat Rev Clin Oncol       Date:  2017-09-19       Impact factor: 66.675

5.  Monocyte-derived IL-1 and IL-6 are differentially required for cytokine-release syndrome and neurotoxicity due to CAR T cells.

Authors:  Margherita Norelli; Barbara Camisa; Giulia Barbiera; Laura Falcone; Ayurzana Purevdorj; Marco Genua; Francesca Sanvito; Maurilio Ponzoni; Claudio Doglioni; Patrizia Cristofori; Catia Traversari; Claudio Bordignon; Fabio Ciceri; Renato Ostuni; Chiara Bonini; Monica Casucci; Attilio Bondanza
Journal:  Nat Med       Date:  2018-05-28       Impact factor: 53.440

6.  An assessment of nonconvulsive seizures in the intensive care unit using continuous EEG monitoring: an investigation of variables associated with mortality.

Authors:  G B Young; K G Jordan; G S Doig
Journal:  Neurology       Date:  1996-07       Impact factor: 9.910

7.  Chronic periodic lateralised epileptic discharges and anti-N-methyl-D-aspartate receptor antibodies.

Authors:  Eisuke Sakakibara; Yukitoshi Takahashi; Yoshiko Murata; Go Taniguchi; Daichi Sone; Masako Watanabe
Journal:  Epileptic Disord       Date:  2014-06       Impact factor: 1.819

8.  Seizure burden is independently associated with short term outcome in critically ill children.

Authors:  Eric T Payne; Xiu Yan Zhao; Helena Frndova; Kristin McBain; Rohit Sharma; James S Hutchison; Cecil D Hahn
Journal:  Brain       Date:  2014-03-04       Impact factor: 13.501

Review 9.  Neurotoxicity Associated with CD19-Targeted CAR-T Cell Therapies.

Authors:  Juliane Gust; Agne Taraseviciute; Cameron J Turtle
Journal:  CNS Drugs       Date:  2018-12       Impact factor: 5.749

Review 10.  ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells.

Authors:  Daniel W Lee; Bianca D Santomasso; Frederick L Locke; Armin Ghobadi; Cameron J Turtle; Jennifer N Brudno; Marcela V Maus; Jae H Park; Elena Mead; Steven Pavletic; William Y Go; Lamis Eldjerou; Rebecca A Gardner; Noelle Frey; Kevin J Curran; Karl Peggs; Marcelo Pasquini; John F DiPersio; Marcel R M van den Brink; Krishna V Komanduri; Stephan A Grupp; Sattva S Neelapu
Journal:  Biol Blood Marrow Transplant       Date:  2018-12-25       Impact factor: 5.742

View more
  1 in total

Review 1.  Clinical Presentation, Risk Factors, and Outcomes of Immune Effector Cell-Associated Neurotoxicity Syndrome Following Chimeric Antigen Receptor T Cell Therapy: A Systematic Review.

Authors:  Shakira J Grant; Alyssa A Grimshaw; Juliet Silberstein; Donna Murdaugh; Tanya M Wildes; Ashley E Rosko; Smith Giri
Journal:  Transplant Cell Ther       Date:  2022-03-11
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.